Related Experiment Video

Updated: May 22, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Kinase inhibitor conjugates

Stefan Harmsen1, Robbert Jan Kok

  • 1Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Current Pharmaceutical Design
|May 11, 2012
PubMed

Insights

Kinase inhibitors are potent cancer drugs, but off-target effects and resistance limit their use. Conjugating these agents to carriers improves targeted delivery, enhancing treatment options for cancer and other diseases.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Delivery

Background:

  • Kinase inhibitors represent a significant advancement in cancer therapy due to their potency and safety.
  • However, their clinical application is hampered by off-target toxicities and acquired resistance.
  • These limitations compromise the long-term efficacy of kinase inhibitor treatments.

Purpose of the Study:

  • To review strategies for overcoming the limitations of kinase inhibitors.
  • To highlight the role of carrier-mediated targeted delivery systems.
  • To explore the potential of targeted kinase inhibitors for various diseases.

Main Methods:

  • Review of current literature on kinase inhibitor conjugation and targeted delivery.
  • Analysis of approaches for cellular and intracellular targeting.
  • Discussion of disease applications beyond cancer.

Main Results:

  • Conjugation of kinase inhibitors to carriers facilitates targeted delivery.
  • Targeted delivery can mitigate off-target toxicities.
  • Targeted approaches show promise in overcoming drug resistance.

Conclusions:

  • Targeted delivery systems offer a promising strategy to enhance the therapeutic index of kinase inhibitors.
  • This approach holds potential for treating not only cancer but also other diseases driven by deregulated kinase signaling.
  • Further development of targeted kinase inhibitors could lead to more effective and safer treatment options.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...